187 related articles for article (PubMed ID: 16733849)
1. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha.
Lebensztejn DM; Sobaniec-Lotowska ME; Kaczmarski M; Voelker M; Schuppan D
World J Gastroenterol; 2006 Jun; 12(21):3338-43. PubMed ID: 16733849
[TBL] [Abstract][Full Text] [Related]
2. Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B.
Lebensztejn DM; Sobaniec-Łotowska ME; Bauer M; Kaczmarski M; Voelker M; Schuppan D
Eur J Gastroenterol Hepatol; 2005 Aug; 17(8):843-8. PubMed ID: 16003134
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system.
Ninomiya T; Yoon S; Hayashi Y; Sugano M; Kumon Y; Seo Y; Shimizu K; Kasuga M
J Gastroenterol Hepatol; 1998 Jan; 13(1):68-74. PubMed ID: 9737575
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
5. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
Mitsuda A; Suou T; Ikuta Y; Kawasaki H
J Hepatol; 2000 Apr; 32(4):666-72. PubMed ID: 10782917
[TBL] [Abstract][Full Text] [Related]
6. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
Tanwar S; Trembling PM; Hogan BJ; Srivastava A; Parkes J; Harris S; Grant P; Nastouli E; Ocker M; Wehr K; Herold C; Neureiter D; Schuppan D; Rosenberg WM
Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):289-296. PubMed ID: 27906753
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of interferon-treated chronic hepatitis C and serum hepatic fibrosis markers.
Ueno T; Ide T; Hashimoto O; Uchimura Y; Torimura T; Kumashiro R; Inuzuka S; Sata M
Hepatogastroenterology; 2001; 48(40):1124-8. PubMed ID: 11490815
[TBL] [Abstract][Full Text] [Related]
9. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
J Gastroenterol; 2000; 35(2):105-11. PubMed ID: 10680665
[TBL] [Abstract][Full Text] [Related]
10. Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C.
Nøjgaard C; Johansen JS; Krarup HB; Holten-Andersen M; Møller A; Bendtsen F;
Scand J Gastroenterol; 2003 Jun; 38(6):659-65. PubMed ID: 12825876
[TBL] [Abstract][Full Text] [Related]
11. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
Serejo F; Costa A; Oliveira AG; Ramalho F; Batista A; De Moura MC
Dig Dis Sci; 2001 Aug; 46(8):1684-9. PubMed ID: 11508668
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C.
Boeker KH; Haberkorn CI; Michels D; Flemming P; Manns MP; Lichtinghagen R
Clin Chim Acta; 2002 Feb; 316(1-2):71-81. PubMed ID: 11750276
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease.
El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS
Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620
[TBL] [Abstract][Full Text] [Related]
14. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease.
Yamada M; Fukuda Y; Nakano I; Katano Y; Takamatsu J; Hayakawa T
Acta Haematol; 1998; 99(4):212-6. PubMed ID: 9644299
[TBL] [Abstract][Full Text] [Related]
15. Histological outcome of chronic hepatitis B in children treated with interferon alpha.
Maria Elzbieta SL; Marek LD
World J Gastroenterol; 2005 Dec; 11(45):7179-82. PubMed ID: 16437668
[TBL] [Abstract][Full Text] [Related]
16. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy.
Guéchot J; Loria A; Serfaty L; Giral P; Giboudeau J; Poupon R
J Hepatol; 1995 Jan; 22(1):22-6. PubMed ID: 7751583
[TBL] [Abstract][Full Text] [Related]
17. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.
Fontana RJ; Goodman ZD; Dienstag JL; Bonkovsky HL; Naishadham D; Sterling RK; Su GL; Ghosh M; Wright EC;
Hepatology; 2008 Mar; 47(3):789-98. PubMed ID: 18175357
[TBL] [Abstract][Full Text] [Related]
18. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
Martinez SM; Fernández-Varo G; González P; Sampson E; Bruguera M; Navasa M; Jiménez W; Sánchez-Tapias JM; Forns X
Aliment Pharmacol Ther; 2011 Jan; 33(1):138-48. PubMed ID: 21083589
[TBL] [Abstract][Full Text] [Related]
19. Histological response to interferon alfa-based therapies in hepatitis C.
Lee SS
Semin Liver Dis; 2004; 24 Suppl 2():55-60. PubMed ID: 15346247
[TBL] [Abstract][Full Text] [Related]
20. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN.
Fabris P; Marranconi F; Bozzola L; Biasin MR; De Lazzari F; Plebani M; Benedetti P; Tositti G; Pellizzer G; Stecca C; de Lalla F
J Gastroenterol; 1999 Jun; 34(3):345-50. PubMed ID: 10433010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]